Brief: Alx Oncology Announces First Patient Dosed In Phase 2 Investigator-Sponsored Trial Of Evorpacept
11/08/2022 12:33
Aug 11 (Reuters) - ALX Oncology Holdings Inc ALXO.O :
* ALX ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN PHASE 2
INVESTIGATOR-SPONSORED TRIAL OF EVORPACEPT IN COMBINATION WITH
CETUXIMAB AND PEMBROLIZUMAB IN PATIENTS WITH ADVANCED COLORECTAL
CANCER
Source text for Eikon: ID:nGNX3p0C89
Further company coverage: ALXO.O
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing